In reading a research from the Cyprus Institute of Neurology and Genetics (CING) Neurology Clinic there was a 30-month study completed with 80 participants split into four groups. The goal was to determine if omega-3, omega-6 with PLP10 vitamins reduced the number of annualized relapse rate (ARR) for MS patients. “In this small proof-of-concept, randomized, double-blind clinical trial; the PLP10 treatment significantly reduced the ARR and the risk of sustained disability progression without any reported serious adverse events. Larger studies are needed to further assess the safety and efficacy of PLP10.” (NCBI)

To learn more about PLP10 and this study checkout: http://www.ncbi.nlm.nih.gov/pubmed/23599375 and http://apps.who.int/trialsearch/trial.aspx?trialid=ISRCTN87818535.